Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Eli Lilly's experimental combination regimen produced greater weight loss than a high dose of tirzepatide alone in a mid-stage trial of patients with obesity, the company said Wednesday. The result puts the closely watched pairing of tirzepatide with eloralintide, Lilly's amylin drug, on a path to late-stage testing.

Lilly plans to start Phase 3 trials on the combination at the end of the year. That timeline gives the program a defined next milestone: the jump from mid-stage data to pivotal studies.

The comparator matters. Tirzepatide is Lilly's top-selling drug, and the combination beat it at a high dose, not a low or starting dose. Interpretation: the result suggests adding an amylin-targeting drug can extend efficacy beyond what tirzepatide delivers alone, which is the core thesis behind the regimen.

The announcement also frames a possible lifecycle story. If Phase 3 confirms the mid-stage signal, Lilly would hold a follow-on obesity option built around its best-selling product rather than a standalone replacement. That is analysis, not a company claim.

Lilly's Phase 3 start is guided for year-end, so the next hard datapoint is still months away. Until then, the stock's reaction to this readout is the main market signal.